Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004092 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00004092 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 72 participants.
The verdict
NCT00004092, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different regimens of combination chemotherapy and comparing them to see how well they work in treating patients with high-risk primary stage II or stage III breast cancer.
Interventions
- DRUG carboplatin
- DRUG cyclophosphamide
- DRUG paclitaxel
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 1999-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004092
The ClinicalTrials.gov registry entry for NCT00004092 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00004092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004092 about?
NCT00004092 is a clinical study titled "Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different regimens of combination chemotherapy and comparing them t...
What is the current status of trial NCT00004092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 1999-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00004092?
The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), paclitaxel (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00004092?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.